{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:22Z","timestamp":1790744182166,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Im vorliegenden Fall trat bei einem Patienten mit multipler Sklerose unter Natalizumab-Therapie ein akuter einseitiger Visusverlust auf. Bei immunsupprimierten Patienten sollte differenzialdiagnostisch eine infekti\u00f6se Genese ber\u00fccksichtigt und mittels diagnostischer Probenentnahme best\u00e4tigt werden. Eine antivirale Therapie ist schon bei klinischem Verdacht auf eine akute retinale Nekrose fr\u00fchzeitig indiziert. Die Evidenz hinsichtlich der Therapiedauer und Applikationsformen ist bislang begrenzt und heterogen, sodass eine individuelle, an klinischen Befund und Immunstatus angepasste Behandlungsstrategie erforderlich ist.<\/jats:p>","DOI":"10.1007\/s00347-026-02528-3","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:49:54Z","timestamp":1790693394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Akute einseitige Visusminderung mit retrobulb\u00e4ren Schmerzen bei bekannter multipler Sklerose\u00a0\u2013 Eine klare Diagnose?","Acute unilateral loss of vision with retrobulbar pain in a patient with known multiple sclerosis\u2014A clear diagnosis?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-2923","authenticated-orcid":false,"given":"Yuhe","family":"Dr\u00fcmmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"L\u00f6w","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebriz","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"12","key":"2528_CR1","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold\u00a0A, Fraser\u00a0CL, Abegg\u00a0M, Alroughani\u00a0R, Alshowaeir\u00a0D, Alvarenga\u00a0R et\u00a0al (2022) Diagnosis and classification of optic neuritis. Lancet Neurol 21(12):1120\u20131134","journal-title":"Lancet Neurol"},{"key":"2528_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ajo.2021.03.057","volume":"228","author":"The Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"The Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification Criteria for Acute Retinal Necrosis Syndrome. Am J Ophthalmol 228:237\u2013244","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"2528_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41433-024-03028-x","volume":"38","author":"D Kalogeropoulos","year":"2024","unstructured":"Kalogeropoulos\u00a0D, Afshar\u00a0F, Kalogeropoulos\u00a0C, Vartholomatos\u00a0G, Lotery\u00a0AJ (2024) Diagnostic and therapeutic challenges in acute retinal necrosis; an update. Eye (Lond) 38(10):1816\u20131826","journal-title":"Eye (Lond)"},{"issue":"3","key":"2528_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/ceo.13500","volume":"47","author":"XN Wu","year":"2019","unstructured":"Wu\u00a0XN, Lightman\u00a0S, Tomkins-Netzer\u00a0O (2019) Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A\u00a0review. Clin Exp Ophthalmol 47(3):381\u2013395","journal-title":"Clin Exp Ophthalmol"},{"key":"2528_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102838","volume":"50","author":"ZLE van Kempen","year":"2021","unstructured":"van Kempen\u00a0ZLE, van Rossum\u00a0JA, Hoogervorst\u00a0E, Strijbis\u00a0E, Toorop\u00a0A, Bosscha\u00a0MI et\u00a0al (2021) Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients. Mult Scler Relat Disord 50:102838","journal-title":"Mult Scler Relat Disord"},{"key":"2528_CR6","doi-asserted-by":"crossref","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol 2020; 11.","DOI":"10.3389\/fimmu.2020.549842"},{"issue":"16","key":"2528_CR7","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser\u00a0SL, Kappos\u00a0L, Montalban\u00a0X, Craveiro\u00a0L, Chognot\u00a0C, Hughes\u00a0R et\u00a0al (2021) Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology 97(16):e1546\u2013e1559","journal-title":"Neurology"},{"issue":"1","key":"2528_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.survophthal.2023.09.004","volume":"69","author":"I Putera","year":"2024","unstructured":"Putera\u00a0I, Ridwan\u00a0AS, Dewi\u00a0M, Cifuentes-Gonz\u00e1lez\u00a0C, Rojas-Carabali\u00a0W, Sitompul\u00a0R et\u00a0al (2024) Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis. Surv Ophthalmol 69(1):67\u201384","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"2528_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.oret.2020.07.012","volume":"5","author":"MR Debiec","year":"2021","unstructured":"Debiec\u00a0MR, Lindeke-Myers\u00a0AT, Shantha\u00a0JG, Bergstrom\u00a0CS, Hubbard\u00a0GB, Yeh\u00a0S (2021) Outcomes of Combination Systemic and Intravitreal Antiviral Therapy for Acute Retinal Necrosis. Ophthalmol Retina 5(3):292\u2013300","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"2528_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ophtha.2016.11.007","volume":"124","author":"SD Schoenberger","year":"2017","unstructured":"Schoenberger\u00a0SD, Kim\u00a0SJ, Thorne\u00a0JE, Mruthyunjaya\u00a0P, Yeh\u00a0S, Bakri\u00a0SJ et\u00a0al (2017) Diagnosis and treatment of acute retinal necrosis: a report by the American Academy of Ophthalmology. Ophthalmology 124(3):382\u2013392","journal-title":"Ophthalmology"},{"key":"2528_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.916113","volume":"2","author":"F Hoogewoud","year":"2022","unstructured":"Hoogewoud\u00a0F, Rossi\u00a0DC, Stappler\u00a0T, Guex-Crosier\u00a0Y (2022) Acute retinal necrosis: A mini review. Front Ophthalmol (Lausanne) 2:916113","journal-title":"Front Ophthalmol (Lausanne)"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02528-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:26Z","timestamp":1790741546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02528-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":11,"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02528-3","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.\u00a0Dr\u00fcmmer, K.\u00a0L\u00f6w, A.\u00a0Lentzsch, T.U.\u00a0Krohne und L.\u00a0Altay geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}